Issue Date: March 14, 2011
GSK Ends Pact With Targacept
GlaxoSmithKline and Targacept have ended their research collaboration, which was established in 2007 to find compounds that target neuronal nicotinic receptors. The pact is a casualty of ongoing shifts in internal R&D at GSK, which is paring its neurosciences research. Targacept regains full rights to the compounds discovered during the agreement, which centered on five therapeutic areas: pain, smoking cessation, addiction, obesity, and Parkinson’s disease. GSK paid Targacept $45 million throughout the lifetime of the agreement, a figure that includes a $15 million equity investment. When announced in 2007, the deal was touted as worth up to $1.5 billion in milestones for Targacept.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society